ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression

ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression

Glioblastoma (GBM) is a malignant brain tumor, commonly treated with temozolomide (TMZ). Upregulation of A disintegrin and metalloproteinases (ADAMs) is correlated to malignancy; however, whether ADAMs modulate TMZ sensitivity in GBM cells remains unclear. To explore the role of ADAMs in TMZ resista...

Full description

Bibliographic Details
Main Authors:	Jen-Tsung Yang, I-Neng Lee, Cheng Huang, Hsiu-Chen Huang, Yu-Ping Wu, Zhi-Yong Chong, Jui-Chieh Chen
Format:	Article
Language:	English
Published:	MDPI AG 2023-04-01
Series:	International Journal of Molecular Sciences
Subjects:	glioblastoma multiforme (GBM) temozolomide (TMZ) micro-RNAs (miRNAs) a disintegrin and metalloproteinase-17 (ADAM17) drug resistance
Online Access:	https://www.mdpi.com/1422-0067/24/9/7703

Similar Items

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
by: Milan Teraiya, et al.
Published: (2023-04-01)

Nitric Oxide Prevents Glioblastoma Stem Cells’ Expansion and Induces Temozolomide Sensitization
by: Luisa Salvatori, et al.
Published: (2023-07-01)

Anticancer Activities of 9-chloro-6-(piperazin-1-yl)-11H-indeno[1,2-c] quinolin-11-one (SJ10) in Glioblastoma Multiforme (GBM) Chemoradioresistant Cell Cycle-Related Oncogenic Signatures
by: Ntlotlang Mokgautsi, et al.
Published: (2022-01-01)

Investigating the Stability of Six Phenolic TMZ Ester Analogues, Incubated in the Presence of Porcine Liver Esterase and Monitored by HPLC
by: Leroy A. Shervington, et al.
Published: (2022-05-01)

Pyroptosis, ferroptosis, and autophagy cross-talk in glioblastoma opens up new avenues for glioblastoma treatment
by: Sicheng Wan, et al.
Published: (2023-05-01)

Glioblastoma Multiforma Tedavisinde Kanser Kök Hücrelerinin Temozolomide Karşı Oluşturdukları Direnç
by: Meryem Alagoz
Published: (2018-06-01)

Isoginkgetin—A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy
by: Maria Antonietta Oliva, et al.
Published: (2022-11-01)

Aloe-Emodin Overcomes Anti-Cancer Drug Resistance to Temozolomide and Prevents Colony Formation and Migration in Primary Human Glioblastoma Cell Lines NULU and ZAR
by: Sabrina Staffieri, et al.
Published: (2023-08-01)

Interference with ADAM17 inhibits proliferation of human cervical cancer cell line HeLa
by: ZHANG Chun-li, QI Jie-hua, HUAN Yu, WU Shou-le, CAI Xu-shan
Published: (2022-02-01)

Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells
by: Luca X. Zampieri, et al.
Published: (2021-11-01)

A Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines
by: Barbara Brandt, et al.
Published: (2023-04-01)

Hypofractionated Radiation Therapy with Temozolomide for Patients with Glioblastoma Multiforme Recursive Partitioning Analyzes Class V and VI
by: Fuzuli Tuğrul, et al.
Published: (2019-09-01)

De Novo Self-Assembling Peptides Mediate the Conversion of Temozolomide and Delivery of a Model Drug into Glioblastoma Multiforme Cells
by: Megan Pitz, et al.
Published: (2022-09-01)

Use of microRNAs as Diagnostic, Prognostic, and Therapeutic Tools for Glioblastoma
by: David Valle-Garcia, et al.
Published: (2024-02-01)

Implication of Lactucopicrin in Autophagy, Cell Cycle Arrest and Oxidative Stress to Inhibit U87Mg Glioblastoma Cell Growth
by: Rossella Rotondo, et al.
Published: (2020-12-01)

A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1
by: Kai Zhao, et al.
Published: (2024-04-01)

MicroRNA-138 Increases Chemo-Sensitivity of Glioblastoma through Downregulation of Survivin
by: Ji-Young Yoo, et al.
Published: (2021-07-01)

Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells
by: Kai Zhao, et al.
Published: (2021-12-01)

Long Non-Coding RNAs in Multidrug Resistance of Glioblastoma
by: Parvaneh Mahinfar, et al.
Published: (2021-03-01)

Temozolomide-associated blepharoconjunctivitis: a case report
by: Tom Kornhauser, et al.
Published: (2024-04-01)

Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle
by: Tao-Chieh Yang, et al.
Published: (2021-05-01)

Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems
by: Daria Petrenko, et al.
Published: (2022-05-01)

Co-administration of temozolomide (TMZ) and the experimental therapeutic targeting miR-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells
by: Ming Chen, et al.
Published: (2023-06-01)

p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme
by: Jiao Meng, et al.
Published: (2024-03-01)

Delta-radiomics Entropy Based on Tumor Heterogeneity Concept – Response Predictor to Irradiation for Unresectable/recurrent Glioblastoma
by: Camil Ciprian MIRESTEAN, et al.
Published: (2022-12-01)

Smart Nanofiber Mesh with Locally Sustained Drug Release Enabled Synergistic Combination Therapy for Glioblastoma
by: Yinuo Li, et al.
Published: (2023-01-01)

Identification of Differentially Expressed Genes in Different Glioblastoma Regions and Their Association with Cancer Stem Cell Development and Temozolomide Response
by: Justin Bo-Kai Hsu, et al.
Published: (2021-10-01)

Investigating acquired temozolomide resistance in adult glioblastoma
by: Wong, ZY
Published: (2020)

Molecular Docking and Molecular Dynamics Studies Reveal Secretory Proteins as Novel Targets of Temozolomide in Glioblastoma Multiforme
by: Sumera, et al.
Published: (2022-10-01)

The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review
by: Ehsan Alimohammadi, et al.
Published: (2020-02-01)

IL-17A Promotes Epithelial ADAM9 Expression in Cigarette Smoke-Related COPD
by: Li D, et al.
Published: (2022-10-01)

Changes of O<sup>6</sup>-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse—A Meta-Analysis Type Literature Review
by: Jonas Feldheim, et al.
Published: (2019-11-01)

Unusual presentation of glioblastoma in the brainstem: a case report of a diffuse pontine glioblastoma multiforme and surgical management
by: Brandon Edelbach, et al.
Published: (2024-03-01)

Role of extent of resection on the survival of glioblastoma multiforme
by: Dipak Chaulagain, et al.
Published: (2023-06-01)

Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review
by: Masoumeh Najafi, et al.
Published: (2023-01-01)

Strategies to Target ADAM17 in Disease: From Its Discovery to the iRhom Revolution
by: Matteo Calligaris, et al.
Published: (2021-02-01)

ADAM Metalloproteinase Domain 17 Regulates Cholestasis-Associated Liver Injury and Sickness Behavior Development in Mice
by: Wagdi Almishri, et al.
Published: (2022-01-01)

Estradiol Induces Epithelial to Mesenchymal Transition of Human Glioblastoma Cells
by: Ana M. Hernández-Vega, et al.
Published: (2020-08-01)

Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil
by: Karoline Almeida Lima, et al.
Published: (2023-04-01)

Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status
by: Qiong Wu, et al.
Published: (2023-10-01)